Compare FDP & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | IRON |
|---|---|---|
| Founded | 1886 | 2017 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 1999 | 2020 |
| Metric | FDP | IRON |
|---|---|---|
| Price | $39.80 | $58.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $103.18 |
| AVG Volume (30 Days) | 213.0K | ★ 544.0K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $4,322,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.75 | $283.52 |
| P/E Ratio | $21.47 | ★ N/A |
| Revenue Growth | ★ 0.98 | N/A |
| 52 Week Low | $29.00 | $30.82 |
| 52 Week High | $43.58 | $99.50 |
| Indicator | FDP | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 37.74 |
| Support Level | $34.76 | $57.81 |
| Resistance Level | $40.75 | $64.00 |
| Average True Range (ATR) | 1.02 | 2.80 |
| MACD | -0.39 | 0.05 |
| Stochastic Oscillator | 5.07 | 12.82 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.